Maxim Group Analysts Give AEterna Zentaris (NASDAQ:AEZS) a $4.00 Price Target

Maxim Group set a $4.00 price target on AEterna Zentaris (NASDAQ:AEZS) (TSE:AEZ) in a research note issued to investors on Wednesday, January 17th. The brokerage currently has a buy rating on the biopharmaceutical company’s stock.

AEZS has been the subject of several other research reports. Zacks Investment Research upgraded AEterna Zentaris from a hold rating to a buy rating and set a $2.50 price target for the company in a report on Tuesday, January 16th. HC Wainwright set a $3.00 price target on AEterna Zentaris and gave the stock a buy rating in a report on Wednesday, November 29th.

Shares of AEterna Zentaris (NASDAQ AEZS) traded down $0.03 during trading on Wednesday, reaching $1.88. The company had a trading volume of 91,474 shares, compared to its average volume of 849,596. AEterna Zentaris has a 1-year low of $0.78 and a 1-year high of $3.75. The company has a market capitalization of $29.43, a P/E ratio of -1.04 and a beta of 0.60.

An institutional investor recently raised its position in AEterna Zentaris stock. JPMorgan Chase & Co. raised its holdings in AEterna Zentaris Inc. (NASDAQ:AEZS) (TSE:AEZ) by 451.5% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 56,800 shares of the biopharmaceutical company’s stock after purchasing an additional 46,500 shares during the quarter. JPMorgan Chase & Co. owned 0.35% of AEterna Zentaris worth $120,000 as of its most recent filing with the Securities and Exchange Commission (SEC). 1.95% of the stock is currently owned by institutional investors and hedge funds.

COPYRIGHT VIOLATION WARNING: This piece was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://www.dispatchtribunal.com/2018/02/13/aeterna-zentaris-aezs-pt-set-at-4-00-by-maxim-group.html.

AEterna Zentaris Company Profile

Aeterna Zentaris Inc is a specialty biopharmaceutical company engaged in developing and commercializing treatments in oncology, endocrinology and women’s health. The Company operates through the biopharmaceutical segment. The Company is engaged in drug development activities and in the promotion of products for others.

Receive News & Ratings for AEterna Zentaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AEterna Zentaris and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply